D-ECCO
11December2018

Obesity in IBD

Marjo Campmans-Kuijpers, D-ECCO Member

Marjo Campmans KuijpersMarjo Campmans-Kuijpers
© ECCO

Although Inflammatory Bowel Disease (IBD) has been historically associated with underweight and malnutrition, rates of obesity have been rising in patients with IBD, as in the general population. Nowadays, 15%–40% of adults with IBD are obese, and an additional 20%–40% are overweight [1]. Obesity is independently associated with higher disease burden and costs of hospitalisation in patients with IBD [2].

Posted in Committee News, D-ECCO, Volume 13, Issue 4

04October2018

Nutrition screening tools in IBD

Catherine Wall, D-ECCO Member

Catherine Wall wrc 2018
Catherine Wall 
© ECCO

Nutrition screening tools are commonly used in clinical practice to identify patients who may be at nutrition risk. Patients identified as being at nutrition risk should be referred for nutritional assessment prior to implementation of a food and nutrition intervention as required. The use of nutrition screening tools can identify those patients most likely to benefit from a dietitian's input and can assist with the allocation of scarce dietetic resources. 

Posted in ECCO News, Committee News, D-ECCO, Volume 13, Issue 3

08June2018

Update on elimination diets

Rotem Sigall-Boneh, D-ECCO Chair

Rotem Sigall Boneh
Rotem Sigall-Boneh
© ECCO

In recent years, there has been increasing evidence that diet has an important role in Inflammatory Bowel Diseases and their management, from the pathogenesis of disease through to treatment and supportive therapy. Exclusive enteral nutrition (EEN) is a well-established dietary therapy that leads to induction of remission and also is associated with mucosal healing in patients with Crohn’s Disease (CD), especially in children. However, adherence to this therapy is low and it is difficult to maintain EEN for a long period. The mechanism by which EEN works is still elusive but several possibilities have been suggested. Accordingly, many groups have sought different dietary strategies to treat patients with CD or UC with several goals: Induction of remission, maintenance of remission and management of gastrointestinal symptoms.

Posted in ECCO News, Committee News, D-ECCO, Volume 13, Issue 2

27April2018

D-ECCO 2018 - The New Committee on the Block has Demonstrated its Mettle

Arie Levine, D-ECCO Member

11 Arie LevineArie Levine © ECCO

This ECCO News Issue is the perfect opportunity for me to express awe and gratitude: awe for the dedicated dietitians of D-ECCO, who have accomplished so much, and gratitude to the Governing Board of ECCO, which detected this emerging need in IBD and supported its development within ECCO, allowing me to be part of the process.

Posted in Committee News, ECCO'18, Congress News, D-ECCO, Volume 13, Issue 1

12December2017

Treatment of functional bowel symptoms in IBD

Miranda Lomer, D-ECCO WG Member

Miranda LomerMiranda Lomer  ©  ECCO

At least a third of patients with inactive IBD have coexisting functional bowel symptoms (e.g.  abdominal pain, bloating, increased flatulence, diarrhoea and/or constipation) and these symptoms may be mistaken for active IBD. Patients may also experience increased anxiety/depression and reduced quality of life. Objective markers of disease activity (histological and inflammatory markers, e.g. faecal calprotectin, C-reactive protein), in conjunction with assessment of clinical symptoms, help to distinguish between functional bowel symptoms and active IBD. Identification of functional bowel symptoms in inactive IBD is important to avoid unnecessary and potentially harmful treatment strategies; on the other hand, active disease should be excluded before establishing that symptoms are functional in nature.

Posted in ECCO News, Committee News, D-ECCO, Volume 12, Issue 4